Advertisement

Topics

Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?

19:48 EDT 3 Jul 2017 | Nature Publishing

The FOURIER trial shows that evolocumab, an injectable monoclonal antibody against PCSK9, decreased the risk of cardiovascular events in high-risk patients receiving statin therapy. The beneficial effects of this drug were consistent with an absolute reduction in LDL cholesterol levels, although studies with a longer follow-up period are needed.

Original Article: Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?

NEXT ARTICLE

More From BioPortfolio on "Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Statins
Statins (or HMG-CoA reductase inhibitors) are a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, which plays a central role in the production of cholesterol in the liver. Increased cholesterol levels have been as...